N/A N=217 Central Venous Access Study
Central Line Catheters
Primary: Adherence to Clinical Guidelines for Catheter Interventions and Management — 12; 0; 0; 11 # of catheter-related incidents
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
N/A N=103 Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants
N/A N=95 AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)
Vascular Access Complication
Primary: Percentage of Participants With Successfully Inserted Peripheral IV Catheter Placement on First Attempt — 85.3 percentage of participants
N/A N=46 Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation
Chronic Kidney Disease · Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Mean Scores of a Questionnaire Evaluating Patient Confidence in Navigating Vascular Access Care Pre- to Post-program Implementation — 8.0; 8.7 score on a scale — p=0.20
N/A N=204 AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
N/A N=168 AMBULATE Continued Access Protocol to Evaluate the Cardiva Mid-Bore Venous Vascular Closure System (VVCS)
Surgical Wound
Primary: Number of Participants With Overall Procedure Success - Effectiveness — 168 Participants
N/A N=164 Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
N/A N=144 VasQ External Support for Arteriovenous Fistula
Arterio-Venous Fistula · ESRD · Steal Syndrome
Primary: Primary Patency of AVF — 88 Participants
Phase 2 N=30 Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis
Renal Failure · End Stage Renal Disease · Vascular Access
Primary: Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAV — 0 participants
Phase 3 N=54 Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
End Stage Renal Disease · AV Fistula · Kidney Failure
Primary: Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis — 49 participants
N/A N=30 Evaluation of the Surfacer System Approach to Central Venous Access
Venous Occlusion
Primary: Number of Participants With Safe Insertion and Patency of Central Venous Access Catheter — 30 participants — p=0.5
N/A N=46 Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)
Kidney Diseases
Primary: Vein Diameter — 1.692; 2.100 millimeters — p=0.012
N/A N=330 IN.PACT™ AV Access IDE Study
Arteriovenous Fistula Stenosis · Arteriovenous Fistula Occlusion · Arteriovenous Fistula
Primary: Target Lesion Primary Patency Rate Through 6 Months — 125; 88 Participants — p=<0.001
N/A N=50 Ultrasound-Guided Peripheral Venous Access Using AccuCath
Intravenous Access
Primary: First Attempt Success Rate — 17; 11 Participants
N/A N=110 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)
Stenosis · Restenosis
Primary: Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events — 106 Participants — p=0.0021
N/A N=72 Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
Renal Failure Chronic Requiring Hemodialysis
Primary: Percentage of Patients With Primary Patency — 48.2; 47.0; 30.6; 34.8 percentage of participants patent
N/A N=100 Technique for Successful Ultrasound-guided Peripheral Vascular Access
Obesity · Vascular Diseases
Primary: Successful First Attempt Peripheral Venous Cannulation — 96 participants
N/A N=158 Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
N/A N=15 Confirmatory Study to Assess the V Needle in End-Stage Renal Disease Patients During In-Clinic Hemodialysis
End Stage Renal Disease
Primary: Percentage of Successful Hemodialysis Sessions — 100; 98.9 percentage of successful sessions — p=.008
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
N/A N=152 Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
PICC · Central Venous Catheter · Central Line
Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271
N/A N=20 Compass Device CVC Trial
Blood Pressure
Primary: Operator Satisfaction — 8 score on a scale
N/A N=420 RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)
Surgical Wound
Primary: Time to Hemostasis (TTH) — 21.4; 4.8 minutes
N/A N=10 Coronal Mode Ultrasound Guided Hemodialysis Cannulation: Comparison With Standard Cannulation Technique
Arteriovenous Fistula, Cannulation
Primary: Infiltration Due to Dialysis Access Cannulation — 5; 7 infiltration events
N/A N=212 Ultrasound Guided Vascular Access in Pediatric Intensive Care Patients
Critical Illness
Primary: Central Line Placement Success — 82; 108 participants — p=<0.001
N/A N=44 Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
Kidney Diseases
Primary: Feasibility- Eligibility for Randomization — 54 Participants
Phase 3 N=355 Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Renal Failure · End Stage Renal Disease · Hemodialysis
Primary: Number of Participants With Loss of Secondary Patency — 29; 34 Participants
N/A N=12 Continued Access Study VIG Anastomotic Connector
Dialysis Access Malfunction
Primary: Cumulative Patency — 5 Participants
N/A N=280 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
Stenosis · Restenosis
Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001